Market Trends Novo Nordisk to test GLP-1’s impact on addiction (NVO:NYSE)By admin8996erT0allMarch 6, 2025 Peter HansenNovo Nordisk (NVO) plans to run studies on how its GLP-1 class of weight loss/diabetes drug can help people…
